Original Articles

New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A


Abstract


Recently new opportunities are emerging for improving the way patients with Haemophilia A are treated. Among these opportunities, efmoroctocog alfa is a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc) produced by recombinant DNA technology with an extended half-life compared with conventional FVIII preparations. The available evidence coming from an Italian HTA report indicates that efmoroctocog alfa provides an effective alternative to conventional FVIII preparations (including standard rFVIIIs) for the management of Haemophilia A. Moreover, by reducing the frequency of injections required, it has the potential to reduce treatment burden, and hence improve adherence to prophylaxis and patient Quality-of-Life. 


Full Text:

PDF


DOI: https://doi.org/10.2427/13247

References



Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Epidemiology, Biostatistics and Public Health

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it (Read more).
Ok


EBPH Epidemiology, Biostatistics and Public Health | ISSN 2282-0930

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.